Soleno Therapeutics Inc (SLNO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Soleno Therapeutics Inc (SLNO) has a cash flow conversion efficiency ratio of 0.108x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($48.70 Million) by net assets ($450.12 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Soleno Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Soleno Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read SLNO current and long-term liabilities for a breakdown of total debt and financial obligations.
Soleno Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Soleno Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ansell Limited
F:PD1A
|
0.031x |
|
The Chefs Warehouse Inc
NASDAQ:CHEF
|
-0.015x |
|
Chengdu Wintrue Holding Co Ltd
SHE:002539
|
-0.032x |
|
Mivne Real Estate KD Ltd
TA:MVNE
|
0.029x |
|
Sigurd Microelectronics Corp
TW:6257
|
0.058x |
|
American States Water Company
NYSE:AWR
|
0.092x |
|
Brookfield Wealth Solutions Ltd.
NYSE:BNT
|
0.026x |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
0.040x |
Annual Cash Flow Conversion Efficiency for Soleno Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Soleno Therapeutics Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Soleno Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $450.12 Million | $46.80 Million | 0.104x | +136.88% |
| 2024-12-31 | $245.11 Million | $-69.10 Million | -0.282x | -78.03% |
| 2023-12-31 | $157.51 Million | $-24.94 Million | -0.158x | +92.12% |
| 2022-12-31 | $10.35 Million | $-20.78 Million | -2.008x | -28.67% |
| 2021-12-31 | $17.79 Million | $-27.77 Million | -1.561x | -181.82% |
| 2020-12-31 | $45.55 Million | $-25.22 Million | -0.554x | +52.36% |
| 2019-12-31 | $14.95 Million | $-17.38 Million | -1.162x | -202.60% |
| 2018-12-31 | $30.41 Million | $-11.68 Million | -0.384x | -2.45% |
| 2017-12-31 | $26.53 Million | $-9.95 Million | -0.375x | +90.46% |
| 2016-12-31 | $3.44 Million | $-13.50 Million | -3.929x | -22.99% |
| 2015-12-31 | $3.22 Million | $-10.30 Million | -3.195x | -836.12% |
| 2014-12-31 | $-10.33 Million | $-4.48 Million | 0.434x | +1756.41% |
| 2013-12-31 | $-37.86 Million | $-885.22K | 0.023x | -77.14% |
| 2012-12-31 | $-34.20 Million | $-3.50 Million | 0.102x | -- |
About Soleno Therapeutics Inc
Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeut… Read more